Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Costs (inflated and discounted) in € by randomization group over a 2-year period

From: Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study)

Average cost per patient in € (SD) First-line coil treatment group Second-line coil treatment group P value
0–12 months after randomization N=50 N=50  
 First coil procedure 14,412 (2358) NA NA
 Second coil procedure (N = 47) 14,022(2471) NA NA
 Rehospitalization 1486 (3352) 674 (1983) 0.15
 Consultations 984 (1053) 987 (1209) 0.24
 Transportation 265 (317) 121 (189) 0.01
 Home oxygen 2222 (1925) 2040 (1933) 0.49
 Monitoring tests 505 (72) 519 (36) 0.29
 Imaging 125 (20) 105 (7) <.0001
Average total cost during the first year a 33,388 (6949) 4446 (2644) <.0001
12–24 months after randomization N = 46b N = 47b  
 First coil procedure (N = 40) NA 14,022 (996) NA
 Second coil procedure (N = 36) NA 13,465 (501) NA
 Rehospitalization 4912 (19,662) 2897 (4,4862) 0.19
 Consultations 460 (630) 647 (1046) 0.005
 Transportation 31 (48) 132 (159) 0.002
 Home oxygen 2076 (1949) 1790 (1887) 0.51
 Monitoring tests 97 (21) 97 (21) 0.44
 Imaging 20 (4) 57 (18) <.0001
Average total cost during the second year for patients alive a 7596 (20,035) 27,867 (12,487) <.0001
0–24 months after randomization N = 50 N = 50  
Total cost for 50 patients per groupc 2,018,781 1,536,027 NA
Average total cost per patient 40,376 (21,173) 30,721 (14,364) 0.07
  1. aPatients who did not have the coil treatment have estimated costs of €0
  2. bPatients alive at 12 months
  3. cThe ITT population. Patients who died or did not have the coil treatment have estimated costs of €0
  4. The bold datas are number of patients, subtotal and total